Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.4290
+0.0079 (1.88%)
At close: Sep 22, 2026, 4:00 PM EDT
0.4340
+0.0050 (1.17%)
After-hours: Sep 22, 2026, 7:04 PM EDT
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $1.16M in the quarter ending June 30, 2026, a decrease of -15.10%. This brings the company's revenue in the last twelve months to $4.50M, down -39.29% year-over-year. In the year 2025, Ensysce Biosciences had annual revenue of $5.07M, down -2.75%.
Revenue (ttm)
$4.50M
Revenue Growth
-39.29%
P/S Ratio
1.85
Revenue / Employee
$450,075
Employees
10
Market Cap
8.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.07M | -143.38K | -2.75% |
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 1.66M |
| Longeveron | 1.19M |
| Exicure | 500.00K |
| CollPlant Biotechnologies | 389.00K |
| Senti Biosciences Holdings | 55.00K |
| Aprea Therapeutics | 5.19K |
| Soligenix | 2.34K |
ENSC News
- 7 days ago - Ensysce Biosciences advances CRPS program at Painweek 2026 - TheFly
- 7 days ago - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation - Accesswire
- 8 days ago - Ensysce professor to speak at FDA public hearing on psychedelic drugs - TheFly
- 8 days ago - Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Accesswire
- 20 days ago - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation - Accesswire
- 22 days ago - Ensysce completes enrollment for final phase of PF614-MPAR-102 study - TheFly
- 22 days ago - Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study - Accesswire
- 4 weeks ago - Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium - Accesswire